Cardiovascular Diseases (CVD) are the biggest cause of death globally and the trends are not any different in India. In India CVDs are the largest causes of mortality, accounting for about 50% of all deaths resulting from Non Communicable Diseases (NCD) and 25% of the overall deaths. About 32 million adults suffer from Cardiovascular Disease in India. Due to changes in lifestyle and recent economic development, the prevalence of risk factors for coronary heart disease has rapidly increased. The overall incidence of heart disease has doubled in India during the last 20 years and this trend is expected to continue. The incidence rate of coronary heart is 16 % in today against 10% a decade back.

 

 

With proliferation of Cath Labs the incidents of intervetions are on a steady rise.The number of coronary interventions performed in India is 100000 annually and by 2020 about 280000 will undergo surgery

 

 

 (All figures and statistics provided above are sourced from HealthQ’s own research conducted in the recent past)

 

 

 

 

 

Listed below are some of the projects we have successful delivered in the field of cardiology:

 

 

 

 

 

 

Project Code

Case Study

Detail

S9486

The effects of Beta Blockers (BB) in patients of hypertension

HealthQ conducted Patient Diaries on 2 sets of patients:- hypertensive patients and non-hypertensive patients and FGD of doctors (GP and non-interventional cardiologist) in 4 cities to understand the difference in effect of BB on both sets of patients. The study was commissioned by a large multinational maker of BB Drugs

A6225

Prevalence of CVD/hypertension in middle aged executives in metro cities

 HealthQ has done an end to end study on prevalence of lifestyle related diseases in mid-level executives of top corporates in 8 cities. The market estimation was done for drugs administered as preventive cure. HealthQ interviewed cardiologist and patients undergoing annual health check ups in 8 different cities. The study was conducted for a  drug maker looking to explore the market for preventive medicine for cardiology.

B9799

Market estimation of Demand pacemakers and Rate-responsive pacemakers

HealthQ has estimating market size of pacemakers in 6 South East-Asian countries of India, Pakistan, Bangladesh, Nepal Bhutan and Sri Lanka. Indian subcontinent has high incidence rate of cardio vascular diseases and the demand for pace makers is rising every year.  A manufacturer based in China wanted to estimate the market size for pacemaker in the Indian subcontinent and HealthQ had done the study for them

J7456

Perception of Coronary Scaffold

IDI and FGD with 75 interventional cardiologists on the perception and usage of drug eluting dissolvable sterns. Dissolvable stents is a new development in field of interventional cardiology and the cardiologist fraternity in India is slow in adopting it. The manufacturer wanted to know the cardiologists opinion on this new development.

O8099

Seek feedback of   ambulatory electrocardiogram from KOL amongst Electrophysiologists (EP)

HealthQ has done 6 cities extensive IDI with KOL amongst EPs for response on a newly launched ambulatory electrocardiogram. Eps with more than 18 year of experience were interviewed for their feedback on a make of ambulatory cardiogram.

F6830

Demand assessment and procurement processes for Haemostatic agents

 HealthQ conducted a study on usage and brand preference, usage rate, current scenario, future potential and procurement processes of hospitals. For the purpose, HealthQ conducted IDIs of Neuro-surgeons,  Cardiac Surgeons, Vascular Surgeons, Gastro-Surgeons, Ortho/spine surgeons, General surgeons and procurement heads across top 32 hospitals in India.

 

 

Click here to see studies from other specialities